RAS question
What is the outlay for Biopharma SHAKTI announced in Budget 2026-27?
Correct answer: (B) ₹10,000 crore.
Biopharma SHAKTI was announced in Budget 2026-27 with an outlay of Rs. 10,000 crore over five years.
Explanation
The outlay is Rs. 10,000 crore over five years, not a one-year token allocation. The PIB Budget 2026-27 note describes Biopharma SHAKTI as a dedicated national initiative meant to strengthen India's end-to-end ecosystem for biologics and biosimilars. That matches the question's explanation: the scheme is designed to help develop India as a global biomanufacturing hub. The key clue is the combination of the scheme name and the five-year horizon. Biopharma SHAKTI is framed as a budget push for domestic development and manufacturing of high-value biopharmaceutical products and medicines, so the figure attached to it in the Budget announcement is Rs. 10,000 crore.
Why the other options are wrong
- (A) Rs. 5,000 crore understates the PIB-stated outlay, which is Rs. 10,000 crore over five years.
- (C) Rs. 15,000 crore is not the amount linked to Biopharma SHAKTI in the Budget 2026-27 note.
- (D) Rs. 20,000 crore doubles the stated allocation and is not supported by the cited PIB Budget note.
Concept
This tests Budget-linked science and technology schemes, especially biotechnology and biomanufacturing policy. Such figures recur in RAS because current policy initiatives are often asked through scheme name, sector and outlay.